SCHEMBL4595659

SCHEMBL4595659

CC(c1ccccc1)N1C(=O)C(=O)c2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 7/20 0.50
TTR P02766 1/20 0.50
ALDH1A1 P00352 6/20 0.47
BCHE P06276 2/20 0.47
CES2 O00748 1/20 0.47
GAA P10253 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TGM2 P21980 1/20 0.44
ALDH2 P05091 2/20 0.44
ALDH3A1 P30838 2/20 0.44
CHRM1 P11229 1/20 0.44
HPGD P15428 1/20 0.43
CASP3 P42574 1/20 0.43
CSNK2B P67870 1/20 0.43
CSNK2A1 P68400 1/20 0.43
LMNA P02545 1/20 0.42
AGTR1 P30556 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
PARK7 Q99497 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5428373 0.87 CES1 (0.50) CES1TTRALDH1A1BCHECES2
SCHEMBL281336 0.82 CES1 (0.50) CES1TTRALDH1A1BCHECES2
SCHEMBL18281472 0.82 CES1 (0.57) CES1TTRALDH1A1BCHECES2
SCHEMBL4199767 0.82 CES1 (0.57) CES1TTRALDH1A1BCHECES2
Hydrochloric Acid SCHEMBL29591677 0.80 CES1 (0.55) CES1TTRALDH1A1BCHECES2
SCHEMBL6925572 0.80 LMNA (0.58) ALDH1A1HPGDCASP3CSNK2BCSNK2A1
SCHEMBL29393294 0.80 LMNA (0.58) ALDH1A1HPGDCASP3CSNK2BCSNK2A1
SCHEMBL607042 0.80 LMNA (0.58) ALDH1A1HPGDCASP3CSNK2BCSNK2A1
SCHEMBL18130273 0.79 CES1 (0.50) CES1TTRALDH1A1BCHECES2
SCHEMBL28251624 0.79 CES1 (0.46) CES1TTRALDH1A1BCHECES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017099695-A1 N-[(AMINOSULFONYL)PHENYL]-2-(1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)-HYDRAZINECARBOTHIOAMIDE DERIVATIVES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS ISTANBUL UNIVERSITESI REKTORLUGU (TR) 2017-06-15 WO disclosed
WO-2008046083-A2 USE OF OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2008-04-17 WO disclosed
EP-1877378-A2 OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2008-01-16 EP disclosed
US-20070105820-A1 Oxindole compounds and their uses as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2007-05-10 US disclosed
WO-2006113864-A2 OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105820-A1 Oxindole compounds and their uses as therapeutic agents OPRL1, OPRK1, TRPV1 CES1 4183/4885TTR 3772/4885ALDH1A1 1136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.